selectivity of current agents. Recent advances in molecular genetics have uncovered new targets for therapeutic development. These include growth factors, growth factor receptors, membrane transduction systems, cytoplasmic signal processes and transcription control. The elucidation of the function of dominantly acting oncogenes and tumour suppressor genes provide a key to a new era of molecular-based pharmacological development.
There are several possibilities for the gene therapy of cancer. The first clinical experiment has already been performed involving the insertion of active tumour necrosis factor genes into tumour infiltrating lymphocytes from a patient with melanoma. Such systems all rely heavily on tumour infiltration by appropriately manipulated cells. A more sophisticated gene therapy system involves the insertion of deleterious genes into vectors which can only be expressed in the tumour or cells of the same tissue of origin when not essential for the body as a whole. CEA, AFP, amylase, calcitonin and prostate specific antigen provide examples of such selectively expressed proteins. Retroviral shuttle vectors containing the relevant tumour or tissue specific promoter linked to a potentially toxic product can be constructed in such a way as to only be expressed when inserted into cells which have the necessary transcriptional machinery.
The manipulation of the somatic cell genetics of cancer cells in vivo is becoming possible by the use of informational drugs which can downregulate the expression of specific genes. It may also be possible in future to replace defective tumour suppressor genes which may reverse at least part of the malignant phenotype. Our laboratory has been investigating the role of secreted growth factor activities in autocrine and paracrine progression of human breast cancer. A survey of tumorigenic human breast cancer cell lines reveals that all secrete heparin binding growth factors capable of inducing clonogenic growth of SW-13 human adrenal carcinoma cells dependent upon fibroblast growth factors for their growth. A variety of known members of the fibroblast growth factor family contribute to these activities as well as yet unidentified activities. We have recently purified, sequenced and cloned a novel heparin binding growth factor produced by some human breast cancer cells which has potent angiogenic potential. In addition, transfection of an expressiLon vector for fibroblast growth factors into human breast cancer cells converts them from hormone dependent to hormone independent growth in athymic nude mice as well as permitting them to form hematogenous metastases. A series of strategies based on binding of heparin binding growth factors to polysaccharides and inhibition of ligand interaction with receptor have been developed which show substantial in vitro and in vivo antitumour and chemoprevention activities with encouraging therapeutic indices. One of these has been brought into clinical trial for patients with advanced cancer. In summary, heparin binding growth factors appear to play a critical role in both autocrine growth of some breast cancers as well as autocrine promotion of angiogenesis. Interference with these pathways is associated with substantial antitumour activity and is an interesting potential target for breast cancer therapy.
tumours. The frequency of activation and the identity of the ras oncogene affected vary dramatically between tumour types: 75% of pancreatic cancers have mutations affecting only Ki-ras codon 12 and 50% of thyroid tumours have mutations affecting all three oncogenes at codon 12, 13 or 61, while breast cancers and female genital tract tumours do not have ras mutations. Activation of ras oncogenes often represent an early critical event in tumorigenesis, and has a powerful dominant transforming effect on epithelial cells in vitro. Identification of ras mutations may be a useful marker for diagnosis of some malignant disease, particularly in situations where only cytological material is available. The presence of ras mutations may be a marker of poor prognosis at least in non-small cell lung cancer. New understanding of the mechanisms involved in the processing and control of ras proteins and of their connections in signal transduction pathways has identified potential targets for therapeutic intervention. These include interference with synthesis and posttranscriptional modifications required for membrane localisation, interference with the GTP/GDP exchange and GTP hydrolysis, blocking of effector molecule function and exploitation of mutant ras peptides as targets for immune therapy. p21ras.proteins are small G-proteins which cycle between a GDP-Sound inactive conformation and a GTP-bound active conformation. The proteins play an important role in signal transduction, but the details are still elusive. Genes encoding p2lras proteins are frequently mutated in human tumors. These mutations abolish the intrinsic GTPase activity of the encoded protein, relating in the malfunctioning of p2lras. Our aim is to investigate the consequences of this malfunctioning for the control of cell proliferation. We have chosen fibroblasts as a model system and we have investigated in which growth factor signal transduction pathway p2lras is involved.
Previously, we have suggeted a possible involvement of p2lras in the insulin signal transduction pathway in rat fibroblasts. Recently, we obtained firm evidence for this hypothesis by measuring the effect of insulin stimulation on the activation of p2lras in NIH/3T3 cells overexpressing the insulin receptor. A conversion of rasGDP into rasGTP (20 to 70% GTP as percentage of total nucleotides bound) was found within 1 min after insulin stimulation. Using cells overexpressing high levels of EGF-or PDGF-receptors, we were not able to detect a significant shift in the GTP/GDP ratio after stimulation with EGF or PDGF, stressing the specificity of insulin in the activation of p2lras (Burgering et al., EMBO J. 10, 1991 , 1103 . Using dominant inhibitory mutants of p2lras we have investigated which cellular effect of insulin stimulation is mediated by p2lras. We found that these mutants inhibit insulin-induced activation of the c-fos promoter (Medema et al., Mol. Cell. Biol, in press ). We conclude from our results that p21ras is involved in insulininduced signal transduction, in particular in the induction of gene expression. Our results do not exclude a role of p2lras in other signal transduction pathways. Two possible mechanisms of insulin-induced activation of p2lras exist. First, insulin could activate an exchange factor, which substitutes GTP for GDP. Secondly, insulin could inhibit the GTPase activating proteins p120GAP and NF1. An indication that P120GAP may mediate insulin-induced activation of p2lras was obtained using the putative phosphatase inhibitor phenylarsine oxide. This compound revealed an insulin-induced phosphorylation of pl20GAP on tyrosines.
We, therefore, propose a model in which pl20GAP mediates insulin-induced activation of p2lras. A similar study on 82 patients with primary transitional cell cancer of the bladder using immunochemistry showed that 18% of the tumours were positive with p53 with strong staining and a further 36% with weaker staining, giving 54% positive tumours. 31% showed staining for the EGF receptor and 15% for cerbB-2. There was a strong association of tumours invading the bladder muscle with p53 and EGFr staining. However, there was no association between p53 and EGF receptor expression.
EGF receptors were assessed on relapsed and recurrent bladder cancers, approximately half the tumours were positive. Using the toxin TGF alpha PE40, high affinity binding sites were demonstrated with a slightly lower affinity compared to EGF. This toxin was also inhibitory to breast cancer cell lines proportional to the level of expression of EGF receptor. These results suggest that a sub-group of invasive bladder tumours could be treated by intravesical cycle therapy with TGF alpha PE40. Similarly, the high expression of p53 in poor prognosis breast cancer and bladder cancer suggests that approaches involving immunological therapy should be evaluated. To assess whether this would be feasible, a study of the loss of HLA in p53 positive tumours was undertaken in breast cancers. Approximately one third of the patients with HLA A2 showed loss of specific class one HLA molecules. However, the majority of patients still showed the expression of this class one molecule, and therefore would be candidates for immunotherapy. We have produced anti-EGFR monoclonal antibodies (MAbs) which block the binding of EGF and TGF-alpha, and can prevent ligand-stimulated activation of EGFR tyrosine kinase. These MAbs have been useful in studies of EGFR function. Experiments utilizing the MAbs to block ligand binding have demonstrated that autocrine stimulation of EGFR phosphorylation can occur via an extracellular pathway, involving TGF-alpha-mediated activation of EGFR on the surface of the cell. The capacity of anti-EGFR MAbs to inhibit cell proliferation has provided evidence for an autocrine stimulatory pathway in cultures of malignant human skin, breast, colon, lung, prostate and kidney cells. Growth of human tumor xenografts can be inhibited in situations where autocrine dependency is demonstrable in cell culture. Imaging studies with anti-EGFR MAb labeled with "' Indium demonstrated selective uptake in xenografts expressing high receptor levels. Based on these observations, a phase I trial was carried out with "' In-labeled anti-EGFR MAb 225 IgGI in patients with advanced squamous cell lung carcinoma, a tumor which invariably expresses large numbers of EGFR. Escalating doses of 225 IgGI were administered as a single intravenous injection over one hour. A dose of 120 mg 225 IgGI could produce saturating antibody levels in the serum for > 3 days and successfully imaged primary tumors as well as metastases > 1 cm in diameter, without producing toxicity. The tumor uptake determined by area-ofinterest scanning was 3.4% of the injected dose, and there was considerable uptake in the liver. This study establishes the principle that anti-EGFR agents which block receptor function can be safely administered to patients and will localize, preferentially, to tumor cells bearing high levels of EGFR. Further studies are exploring the potential efficacy of repeated doses of anti-EGFR MAbs, combinations of antireceptor MAbs, and combined MAb plus chemotherapy. The cellular responses to RA are mediated by two families of transcription factors, which include the RA receptors (RARs) and the retinoid X receptors (RXRs). Although both RAR and RXR respond specifically to RA, they differ substantially from one another in primary structure and ligand specificity. A major question raised by the discovery of two retinoidresponsive systems is whether their functions are independent, interactive, or redundant. One approach to answer this question is to determine whether they share common or distinct downstream target genes. In regard to target sequences we have recently described properties of direct repeats (DRs) of the half-site AGGTCA as hormone response elements. According to our results, spacing of the half-site by 3, 4, or 5 nucleotides determines specificity of response for vitamin D3, thyroid hormone and retinoic acid receptors, respectively. This so-called '3-4-5' rule suggests a simple physiologic code exists in which half-site spacing plays a critical role in achieving selective hormonal response. As part of these studies, we have also identified that the RXR, but not the RAR, is able to activate through a direct repeat spaced by one nucleotide. In contrast, both RAR and RXR are able to commonly activate through a DR with a spacing of 5. Evidence that RXR heterodimers modulate the RA response will be presented. Finally we will discuss the isolation and characterization of a fusion product produced as a consequence of a t(15:17) translocation characteristic of human acute promyelocytic leukemia. This translocation which occurs in the retinoic acid receptor gene generates a unique mRNA which encodes a fusion protein between the retinoic acid receptor alpha (RARa) and a myeloid gene product called PML. Structural analysis reveals that the PML protein is a member of newly recognized protein family that includes a variety of putative transcription factors as well as the recombination-activating gene product (RAG-i).
The abberant PML-RAR fusion product, while typically retinoic acid responsive, displays both cell type and promoter specific differences from the wild type RARo. Because patients with APL can be induced into remission with high dose RA therapy, we propose that the non-liganded PML-RAR is a new class of dominant negative oncogene product.
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The importance of serum concentrations on the efficacy and toxicity of suramin in patients with advanced cancer
'Department Medical Oncology, 2Department Pharmacy, 3Department Neurology, Free University Hospital, 1007 MB Amsterdam, The Netherlands.
Aberrations in growth factor activity have been clearly implicated in the promotion of cancer cell proliferation. Suramin (Sur) has the ability to interfere with these processes in vitro and consequently the drug has been explored as a new anticancer agent in the clinic. Sur levels of >200 mg/L have generally been required before anti-tumour responses have been observed whilst levels > 300 mg/L have been associated with disabling neurotoxicity. This narrow therapeutic window has meant that the control of serum Sur levels has become a crucial issue in the clinical development of this drug. The terminal plasma half life of Sur is 45-55 days which makes a loading regimen designed to achieve therapeutic serum levels (200-300mg/L) followed by intermittent maintenance treatments rational.
We have examined the pharmacokinetics of 5 loading regimens in an attempt to discover the optimum schedule for sur. 1-1.5 gm/week for 3 to 6 weeks produced levels >200mg/L in only one patient (pt) whilst 3/6 developed progressive disease before this level was obtained. 350 mg/m2/ day, as a continuous infusion (4 pts) produced levels of 160-247 mg/L after 6 to 14 days whilst 600 mg/m2/day (4 pts) gave levels of 264-381 in 3-5 days. This latter dose if given by 6 (13 pts) or 12 (5 pts) hour infusion may give peak levels in excess of 400 mg/L after 3 to 5 days.
The weekly maintenance treatments were based on the trough Sur levels and varied from 300 to 900 mg/m2. There was a linear relationship between these doses and the mean increase produced. A regression line drawn through these mean values has an r value of 0.999 (<0.0001). Using these data and knowing the trough and target (_300 mg/L) Sur levels it is possible to calculate how much Sur to give. Using a continuous infusion loading regimen of a few days duration and the above data to calculate the maintenance doses it is possible to maintain the Sur levels within the narrow therapeutic window. Studies conducted until now have failed to adequately achieve this. Further studies are indicated in order to determine the efficacy and toxicity of Sur when the drug levels are maintained within this narrow therapeutic window. Unexpectedly high response rates to Interleukin 2 therapy have been described in renal cell carcinoma and melanoma.
The consensus view is that the true response rate is lower than initially reported and its toxicity, greater. Posterior uveal melanoma is an ocular tumour derived from the ciliary body and choroid. We have studied 20 of these ocular tumours of which 16 were successfully analysed. Cytogenetic reports of this tumour have been limited, with only 23 reported cases. We present the results from 16 tumours. Two tumours had a normal chromosome complement, and a second demonstrated loss of the Y chromosome as the single abnormality. The remaining tumours presented basically pseudodiploid karyotypes with only limited chromosome changes. The most frequently involved chromosomes were 3, 6 and 8. Seven tumours derived from the ciliary body had non random association between monosomy of chromosomes 3 and i(8q). Abnormalities of chromosome 6 involving the long or short arms were found in 9 tumours and two tumours also demonstrated deletion at 11q23. Tumour cells kinetics may indicate prognosis and help to predict response to chemo-or radio-therapy. We have sought to establish the cell kinetics of cervical carcinomas, using the newly available technique of in vivo bromodeoxyuridine labelling.
Sixty patients with stages Ib-IVb cervical carcinoma were given bromodeoxyuridine 6-8 h prior to tumour biopsy. Disaggregated fixed nuclei were stained for bromodeoyxuridine and total DNA content, and analysed by flow cytometry. The proportion of bromodeoxyuridine labelled nuclei (the labelling index, LI), the length of S phase (Ts), and the potential doubling time (Tpot) were then derived.
Fifty two (87%) of tumours produced satisfactory results. Median parameters were: LI 7.5% (range 1.1-22.5), Ts 13.0 h (range 7.4-21.5), Tpot 6.6 days (range 1.5-52.5). Advanced tumours had significantly higher LI Swainsonine (SW) inhibits Mannosidase II during N-linked glycoprotein processing. SW has recently been found to inhibit metastasis in several murine tumour models and to augment the expression of receptors for the lymphokine Interleukin-2(IL-2) on lymphocytes. In this study we have asked whether SW might achieve these antimetastatic effects by potentiating anti-tumour immune responses. The effect of SW on the generation of lymphokine-activated killer (LAK) cells was examined by performing SW dose response curves on the generation of LAK cells from human peripheral blood mononuclear (PMN) cells in response to a fixed concentration of IL-2 (1000 units/ml) in vitro for 3 days. Data are expressed as mean Area-under curve (AUC) units at each concentration of SW. At a concentration of 21g/ml, SW significantly augmented LAK activity from 138 AUC units to 166 (± SED 10) AUC units (P <0.05 by Student's t-test) and was dose-dependant (P <0.05 by ANOVA, n = 6 experiments).
We also studied the effects of SW on the susceptibility of tumour cells to killing by human LAK cells. COL0320 colorectal cancer cells were cultured for 3 days with varying concentrations of SW before being used as target cells in the LAK cell assay which used unmodified PMN activated for 3 days with 1000 units/ml Interleukin-2 (IL-2)-based therapies provide both the greatest response rates and prolongation of survival in patients with advanced malignant melanoma (MM) and renal cell cancer (RCC). Response rates are related to the total IL-2 dose administered but the principal dose-limiting toxicity is a capillary leak syndrome (CLS) of obscure aetiology which predominantly afflicts the lung. Severe sepsis is also associated with a similar acute lung injury which is mediated at least in part by activated neutrophils. Tumour necrosis factor (TNF) is a potent activator of neutrophils and may be released during IL-2 infusion. We sought evidence for neutrophil activation in 10 patients with advanced MM or RCC who developed CLS during a 5-day therapeutic infusion of IL-2. Plasma TNFa levels were measured before (baseline) and on days 1 and 5 of the infusion. Simultaneously, the expression of the neutrophil activation marker CD llb and neutrophil production of H202 were measured by flow cytometry and are expressed as the mean ( ± SEM) of the mean channel fluorescence (MCF) for each parameter. Plasma TNFa levels are elevated within 24 hours of beginning IL-2 infusion and this is accompanied by phenotypic and functional neutrophil activation. This is strong evidence of a role for activated neutrophils in IL-2-induced CLS and suggests means for modifying IL-2 toxicity without necessarily diminishing its therapeutic efficacy.
Localisation of BHRFI to the mitochondria by immunoelectron microscopy: implication for a role in preventing cell death by apoptosis BHRFI is an Epstein-Barr virus gene of unknown function which is expressed at the interface between the latent and lytic cycles'. Cell fractionation studies have indicated it is associated with the mitochondria. BHRFI has 40% homology with the bcl2 gene2 which is deregulated in at least 90% of cases of follicular non-Hodgkin's lymphoma. Bc12 is expressed at the inner mitochondrial membrane and deregulation appears to extend cell survival by interrupting cell death by apoptosis3. BHRFI and bcl2 therefore may have functional equivalence.
To explore the function of BHRFI we have examined an EBV-genome positive cell line, B95.8, using low temperature embedding immunoelectron microscopy. SU-DHL4, a cell line which expresses bcl2 was also studied. B95.8 cells in log phase growth were cultured in either standard (10% foetal calf serum) or stressed (foetal calf serum absent) conditions for three days. SU-DHL4 cells in log phase growth were cultured in standard conditions. Cells were then pelleted, washed, embedded in resin and 0.1 p sections prepared for electron microscopy. Expression of BHRFI and bcl2 were determined using the 5B11 and 100 antibody respectively. Patients received a median of 6 weeks of treatment with a range of 3-10 weeks. 16 patients achieved CR, 11 of these with surgery immediately following chemotherapy for removal of residual masses (8 Retroperitoneal lymph node dissection, and 3 thoracotomy out of which 6 showed foci of mature teratoma, and 5 necrosis only). 11 of these continue in CR with a median follow up of 14 months (range 6-60 months). 'CRC Labs, University of Dundee, Dundee, UK.
The p53 gene encodes a 393 amino acid nuclear phosphoprotein which is now thought to act as a tumour suppressor. Alterations in the structure of the gene (usually either allele loss and/or mutation) are common in many human cancers. The wild type protein has a very short half-life and rapidly disappears from the cell. Mutations, which appear to confer stability, lead to abnormal acccumulation of protein which can be detected immunohistochemically.
We have used polyclonal antibody CM-1 (Midgeley et al., manuscript submitted) raised against a construct of the entire p53 protein, in an immunohistochemical study of breast carcinoma. Optimum conditions have been established for the immunohistochemical detection of the protein in formalin fixed paraffin-embedded tissue. Positive nuclear staining, ranging from weak to very strong, is seen in approximately 70% of cases of infiltrating carcinoma. Care must be taken when interpreting lack of positive staining as this could occur either when the p53 gene is unaltered or when both alleles have been lost. Staining patterns have been related to tumour morphology and a significant association has been found between strong staining and poorly differentiated grade III infiltrating ductal carcinomas.
Early work on ductal carcinoma in situ suggests a lower incidence of positive staining than occurs in infiltrating tumours. No relationship has been found, so far, between staining for p53 and the morphology of the in situ tumours. Recent evidence links the Li-Fraumeni syndrome to inherited mutations within exon 7 of the p53 gene*. Since an excess of breast cancer is found in this syndrome, and somatically acquired mutations of exons 5-9 of the p53 gene are a common feature of sporadic breast cancer, these findings have prompted speculation that germline p53 mutations may be important in familial breast cancer. We have examined lymphocyte DNA from 42 individuals with a strong family history of breast cancer for germline mutations in exons 5-9 of the p53 gene. These individuals were from 26 families and in all families the index case was < 46 years old at diagnosis. In 7 families there were 2 affected first degree relatives aged <45 at diagnosis and in 12 families there were 3 affected first degree relatives, 2 of whom were <45 at diagnosis. In 15 families, 2 affected members were examined. The PCR amplification products of exons 5, 6, 7, and 8 + 9 were examined by single-stranded conformational polymorphism analysis (SSCP) and for exon 7 the PCR product, synthesised using a biotinylated primer, was also solid phase-sequenced using streptavidin-coated magnetic beads.
Mutations in exon
No germline mutations were detected by SSCP in exons 5-9 of the p53 gene. We have prepared two cDNA libraries from the mRNA of oestrogen stimulated breast cancer cells (ZR-75-1 and T-47D-5). A total of ten genes (pLIV-1, pLIV-2 (pS2) and pSyd [1] [2] [3] [4] [5] [6] [7] [8] have been isolated whose mRNAs are increased by oestrogen (2.5-16 fold) and reduced by antioestrogens. In order to determine their potential as prognostic markers in the management of breast cancer we have measured the expression of four genes (pLIV-1, pLIV-2; pSyd 3 and pSyd 8) in 118 primary breast tumours which were also immunohistochemically assayed for ER, PgR, ErbB2, EGFR, Ki67 and pS2. All four genes were expressed at higher levels in tumour compared to those found in normal breast tissue and cell lines. In addition, pSyd3 and 8 sequences were more abundant than their pLIV-l & 2 counterparts. Both pLIV-1 and -2 showed a strong correlation with ER status with expression increasing with increased cellular ER positivity. An inverse relationship between ER and EGFR levels was observed and was reflected in pLIV-1 and -2 mRNA levels decreasing with increasing cellular EGFR staining. In contrast to pLIV-1 and pLIV-2, pSyd-3 and -8 were expressed in both ER -and ER + tumours and showed increased expression with increasing cellular proliferatin as shown by Ki-67 staining.
In conclusion, whilst pLIV-1 and pS2 levels appear to be associated with estrogen responsive pathways, pSyd3 and 8 are more closely linked to cellular proliferation. Since an increase in proliferation is associated with a loss of hormone sensitivity (Nicholson et al., 1991, Eur. J. Cancer, 27, 908-913) Although clearly of great clinical value in the treatment of breast cancer, Tamoxifen has been shown to be a partial oestrogen agonist both in vitro and in vivo.
Using cell lines and clones of oestrogen-induced, and spontaneously arising hormone-responsive rat mammary tumours, we have compared the oestrogenic and anti-oestrogenic effects of Tamoxifen and two analogues. This has been achieved by assaying drug action under conditions of physiological hormone levels (antagonist assay) or of oestrogen deprivation (agonist assay).
In vitro, cell lines were selected which showed inhibition of growth in the presence of phenol-red free medium and DCC stripped FCS. Under these conditions, both Tamoxifen and two analogues (Todo-tamoxifen and Pyrolidino-iodo-tamoxifen) were able to stimulate growth, as did oestradiol. In the presence of DMEM + 10% FCS (normal growth conditions) Tamoxifen inhibited cell growth and both analogues gave consistently better results.
In vivo tumours were implanted into OOX female rats. Cell lines were chosen which, under these conditions, would not develop without additional oestrogen. Groups of rats were dosed with TAM compounds at 2.4 mg/kg. Again we were able to show similar oestrogenic effects of all 3 compounds, although in normal animals, the two analogues have shown greater inhibitory effects on tumour growth than the parent compound.
These models offer a rapid and clinically relevant tumour assay system in which to screen separately for oestrogenic and anti-oestrogenic actions of new compounds. The level of erbB-2 transcription was examined by nuclear run-on assays. Comparison of a non-tumourigenic cell line with baseline erbB-2 expression and malignant cell lines with erbB-2 overexpression has demonstrated a 3-fold increase in erbB-2 transcription in the malignant cell type.
Currently transcriptional control of the erbB-2 promoter in both types of cell line is being examined by short-term transfection of a series of erbB-2 promoter-CAT reporter gene constructs. Our results will be presented. We have developed a method for expressing genes specifically in mouse mammary epithelium in vivo. Normal epithelial cells are isolated from an adult mouse and maintained in culture for four days. During this time, genes are introduced into the cells using non-replicating retroviruses. The altered cells are transplanted into the mammary fat-pad of another mouse from which all the endogenous epithelium has been removed by surgery (a cleared fat-pad). The transplanted cells reconstitute an epithelial 'tree' in which some of the cells express the introduced gene. This is a versatile model for studying growth, development and tumourigenesis in the mammary gland as a wide variety of genes can be introduced and their effect on the epithelial cells determined in their natural tissue environment.
The system has been used to investigate the effect of several oncogenes on the growth and development of the mammary gland. Introduction of the v-myc oncogene alone led to a mild hyperplasia in the gland where the epithelial ducts packed more closely than usual (Edwards, Ward & Bradbury, 1988, Oncogene, 2, 407). v-Ha-ras alone seemed to inhibit the growth of transplants as many mammary glands into which v-Ha-ras-containing cells were transplanted were devoid of epithelial growth. In those glands where there was some growth it was often abnormal, resembling hyperplastic alveolar nodules, a preneoplastic lesion of mouse mammary gland. When both oncogenes were introduced simultaneously tumours resulted in a high percentage of the animals (Bradbury, Sykes & Edwards, 1991, Int. J. Cancer, 48, 908) . Other oncogenes shown to have effects on the growth pattern include int-i which caused vigorous hyperplasia in which the gland was packed with epithelium showing sidebranching like early pregnancy. We have used allele loss studies to indicate areas of the genome in which tumour suppressor gene inactivation may contribute to this disease.
In a preliminary investigation of 20 tumours, we described significant rates of allele loss from at least two loci on chromosome 17'. Approximately 50% of tumours showed loss from the p53 locus (17pl3) while 75% showed loss with the probe pTHH59 (17q23-25).
We have now extended this investigation to a bank of 80 tumours and related allele loss at these two loci to histopathological type and stage of disease. Allele loss at p53 (17pl3) was observed in serous, mucinous and endometrioid tumours but was more prevalent in stage III/IV disease than stage I/II. Allele loss in the region of the probe pTHH59 17q23-25 was also observed in the three histological subtypes and was high in both early and late stage disease.
We have used additional 17q probes to define the region of the loss on this chromosome arm. Partial allele losses were observed in 11 cases. The results are consistent with a target gene mapping to the region extending between the markers pTHH59 (17q23-25) and p05626 (17q25). A number of putative growth factors (GFs) have been implicated in the maintenance and progression of breast cancer. We have investigated the presence of fibroblast growth factor-like (FGF-like) substances released from breast tissues and cultured cell lines into serum free conditioned medium after 24 and 72 h using the NR6 bioassay.
After 24 h the conditioned medium (CM) from cancers fell into two distinct groups, one third (15/45) were found to contain a high level of NR6 growth promoting activity, whilst the other two thirds had low level activity. The tumours with a high level of activity were associated with vascular invasion (p = 0.04). However, after a further 48 h, the CM from all cancers (n = 52) contained only low level activity. In twenty-two cases this activity was found to be heat stable and these cancers were significantly more likely to have metastasised to the regional lymph nodes (p = 0.01).
CM (72 h Our studies have recently shown (Nature, 349, 612, 1991) We have used the polymerase chain reaction and oligonucleotide hybridisation to detect point mutations of N, H, and K RAS in benign and dysplastic naevi, primary and metastatic melanoma.
Mutations were observed in 6 out of 26 naevi (23%), 9 out of 42 primary tumours (22%) and 9 out of 28 metastatic melanomas (32%), with K12 being the most frequently identified mutation. Of the 22 primary melanomas with lymph node involvement, there were 9 mutations (41 %), each occurring in a separate patient. There were no patients in which the mutation was maintained from the primary to the secondary tumour. Of these 22 patients, those with a mutation at some stage of the disease had significantly reduced survival times of 25 months compared to 54 months in those without mutations (p <0.05).
In the naevi all 6 mutations were found in the 9 removed following a significant increase in size, the presence of RAS mutations correlating strongly with clinical growth (p<0.001). No XIII, 60, 1991) . In this study we have examined the proliferative response of these cell lines to EGF under a variety of culture conditions. ZR-75-1 cells express 4,340 ± 460 EGFR sites/cell and failed to respond to EGF in serum-containing culture conditions. In serum-free medium (SFR) containing insulin (5 x 10-7M) and oestradiol (10-8M) The receptor for epidermal growth factor (EGFR) and transforming growth factor a (TGFa) are often overexpressed by squamous cell and other carcinomas and these receptors may therefore form targets for antibody directed therapy. We have produced a series of rat mAbs that recognise the exter- The overexpression of receptors for epidermal growth factor by squamous cell carcinomas and of the related protooncogene c-erbB-2 (pl85) by adenocarcinomas may provide useful targets for specific antibodies. The product of the c-erbB-2 gene is overexpressed in some 20% of breast and ovarian carcinomas and patients whose tumours overexpress the c-erbB-2 P185 have a poor prognosis. We have prepared a series of rat monoclonal antibodies that bind to one of five non-overlapping epitope clusters on the external domain of the c-erbB-2 P185. All of the antibodies immunoprecipitate the 185 kD protein and none binds to the related EGF receptor. One of these antibodies (ICR12, rat IgG2a) binds to p185 in Western blots and stains formol-saline fixed paraffin embedded material. This antibody, which is of high affinity (0.2nM) has been found to localise specifically and stably to xenografted breast and ovarian tumours in nude mice (up to 20% injected dose/g) when labelled with Indium-111, Iodine-125 or the positron emitter Iodine-124. Under these conditions tumour uptake of a control, isotype matched antibody was less than 4% i.d./g. Tumour xenografts of 5 mm diameter were successfully imaged at 24,48 and 120 h using the RMH-ICR MUP-PET camera. ICR12 labelled with Iodine-124 is currently being evaluated in an imaging trial in patients with breast cancer at the Royal Marsden Hospital, Sutton.
